BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) and Ernexa Therapeutics (NASDAQ:ERNA – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for BioMarin Pharmaceutical and Ernexa Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioMarin Pharmaceutical | 1 | 7 | 15 | 1 | 2.67 |
| Ernexa Therapeutics | 1 | 1 | 1 | 0 | 2.00 |
BioMarin Pharmaceutical currently has a consensus price target of $89.17, indicating a potential upside of 55.95%. Ernexa Therapeutics has a consensus price target of $30.00, indicating a potential upside of 913.51%. Given Ernexa Therapeutics’ higher probable upside, analysts clearly believe Ernexa Therapeutics is more favorable than BioMarin Pharmaceutical.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| BioMarin Pharmaceutical | 2.14% | 5.32% | 3.69% |
| Ernexa Therapeutics | N/A | -305.93% | -169.86% |
Insider and Institutional Ownership
98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are owned by institutional investors. 0.7% of BioMarin Pharmaceutical shares are owned by insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares BioMarin Pharmaceutical and Ernexa Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioMarin Pharmaceutical | $3.41 billion | 3.25 | $348.90 million | $0.37 | 154.54 |
| Ernexa Therapeutics | $580,000.00 | 8.32 | -$14.08 million | ($14.35) | -0.21 |
BioMarin Pharmaceutical has higher revenue and earnings than Ernexa Therapeutics. Ernexa Therapeutics is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
BioMarin Pharmaceutical has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500. Comparatively, Ernexa Therapeutics has a beta of 2.63, indicating that its stock price is 163% more volatile than the S&P 500.
Summary
BioMarin Pharmaceutical beats Ernexa Therapeutics on 12 of the 15 factors compared between the two stocks.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.
About Ernexa Therapeutics
Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
